Latest News
MEI Pharma doses first patient in cohort-expansion stage of Phase Ib clinical trial of ME-344
31 October 2014 - United States-based MEI Pharma has dosed the first patient in a cohort-expansion stage of its Phase Ib clinical trial of ME-344 in combination with topotecan, it was reported yesterday.

The product is used to treat patients with small cell lung or ovarian cancer who failed initial therapy.

The firm stated that the cohort expansion comes after the initial stage of the trial confirmed that the maximum tolerated dose of ME-344 in combination with topotecan is 10mg/kg, the same dose defined for single agent use. As part of the cohort-expansion stage, the trial is to enroll an additional 40 patients into two cohorts, locally advanced or metastatic small cell lung cancer and ovarian cancer. The Phase Ib trial is intended to evaluate the combination of intravenous ME-344 and topotecan (Hycamtin).

Login
Username:

Password: